国际皮肤性病学杂志    2002 28 (2): 76-79   ISSN: 2096-5540  CN: 32-1880/R  

皮肤T细胞淋巴瘤的系统药物治疗
陈柳青, 曾学思
中国医学科学院、中国协和医科大学皮肤病研究所, 南京210042
收稿日期 2001-10-08  修回日期 null  网络版发布日期 null
参考文献  [1] Diamandidon E,Cohen PR,Kurzrock R.Mycosis fungoides and Sezary syndrome.Blood,1996,88(7):2385-409.
[2] Zackheim HS,Kashani-Sabet M,Hwang ST.Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma:results in twenty-nine pationts.J Am Acad Dermatol,1996,34(4):626-631.
[3] WoUina U,Graefe T,Karte K.Treatment of relapsing or recalcitrant cu-taneous T-cell lymphoma with pegylated lipesomal doxorubicin.J Am Acad Dermatol,2000,42(1 Pt 1):40-46.
[4] Akpek G,Koh HK,Bogen S,et al.Chemotherapy with etoposide,vin-cristine,doxombicin,bolus cyclophesphamide,and oral prednisone in patients with refractory cutaneous T-cell lymphoma.Cancer,1999,86(7):1368-1376.
[5] Coors EA,von den Driesch P.Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluoeortolone therapy.Br J Dermatol,2000,143(1):127-131.
[6] Kurzroek R,Pilat S,Duvie M.Pontestatin therapy of T-cell lymphomas with cutaneous manifestations.J Clin Oncol,1999,17(10):3117-3121.
[7] Kurzrock R.Pontestatin (Nipent) in T-cell lymphomas.Semin Oncel,2000,27(2 Suppl 5):64-66.
[8] Fess FM.Activity of pentostatin (Nipont) in cutaneous T-cell lymphoma:single-agent and combination studies.Semin Oneol,2000,27(2 Suppl 5):58-63.
[9] Kuzel TM,Hurria A,Samuelson E,et al.Phase Ⅱ trial of 2-chloredeoxyadenesine for the treatment of cutaneous T-cell lymphoma.Blood,1996,87(3):906-911.
[10] Zinzani PL,Baliva G,Magagnoli M,et al.Gemcitabine treatment in pre-treated cutaneous T-cell lymphoma:experience in 44 patients.J Clin On-col,2000,18(13):2603-2606.
[11] Siegel KS,Pandolfino T,Guitart J,et al.Primary cutaneous T-cell lym-phoma:review and current eoncepts.J Clin Oncol,2000,18(15):2908-2925.
[12] Hanney JE.From the Food and Drag Administration.JAMA,2000,283(9):1131.
[13] Jumbou O,N' Guyen JM,Tessier MH,et al.I-ong-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interfemn-alfa.Br J Dermatol,1999,140(3):427-431.
[14] Rook All,Wood GS,Yon EK,et al.Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.Blood,1999,94(3):902-908.
[15] Marolleau JP,Baccard M,Flageul B,et al.High-dose recombinant inter-leukin-2 in advanced cutaneous T-cell lymphoma.Arch Dermatol,1995,131(5):574-579.
[16] LeMaistre CF,Saleh MN,Kuzel TM,et al.Phase I trial of a ligand fu-sion-protein (DAB3891L-2) in lymphomas expressing the receptor for in-terleukin-2.Blood,1998,91 (2):399-405.
[17] Saleh MN,IeMaistre CF,Kuzel TM,et al.Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.J Am Acad Dennatol,1998,39(1):63-73.
[18] Olsen E,Duvie M,Frankel A,et al.Pivotal phase Ⅲ trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lym-phoma.J Clin Oncol,2001,19 (2):376-388.
[19] Knox S,Hoppe RT,Maloney D,et al.Treatment of cutaneous T-cell lym-phoma with chimeric onti-CD4 monoclonal antibody.Blood,1996,87 (3):893-899.
[20] Pawson R,Dyer MJ,Barge R,et al.Treatment of T-ceil prolymphocytic leukemia with human CD52 antibedy.J Clin Oncol,1997,15(7):2667-2672.
[21] Lundin J,Osterborg A,Brittinger G,et al.CAMPATH-1H monoclonal an-tibody in therapy for previously treated low-grade non-Hedgkin's lym-phomas:a phase Ⅱ multieenter study.European Study Group of CAM-PATH-1H Treatment in Low-Grade Non-Hedgkin's Lymphoma.J Clin On-col,1998,16(10):3257-3263.

通讯作者: